Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

Rhea-AI Summary

Compugen Ltd. (NASDAQ: CGEN) has announced a scheduled release of its fourth quarter and full year 2022 financial results on February 27, 2023, before the U.S. markets open. The management will conduct a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Interested parties can join the call via telephone or access the live webcast on the company's website. Compugen, based in Israel, specializes in cancer immunotherapy and predictive computational discovery, with product candidates COM701 and COM902 targeting solid tumors, and a partnered program with AstraZeneca in Phase 2 development.

Positive

• Scheduled financial results release on February 27, 2023.
• Management will provide a corporate update, enhancing transparency for investors.
• Ongoing partnership with AstraZeneca for a Phase 2 bispecific program.

Negative

• None.

HOLON, Israel, Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023, before the U.S. financial markets open.  Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally.  The call will be available via live webcast through Compugen's website, located at the following link, Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen currently has one partnered program, namely rilvegostomig (previously AZD2936), a TIGIT/PD-1 bispecific derived from COM902, that is in Phase 2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is in pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com  
Tel: +1 (628) 241-0071  

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2022-results-on-monday-february-27-2023-301744939.html

SOURCE Compugen Ltd.

FAQ

When will Compugen release its fourth quarter 2022 results?

Compugen will release its fourth quarter and full year 2022 financial results on February 27, 2023.

What time is the Compugen conference call on February 27, 2023?

The conference call will be held at 8:30 AM ET on February 27, 2023.

How can I access Compugen's conference call?

The conference call can be accessed via telephone at 1-866-744-5399 (U.S.) or +972-3-918-0644 (international), and also via live webcast on the company's website.

What are the key product candidates of Compugen?

Compugen's key product candidates include COM701 and COM902, targeting cancer immunotherapy.